Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		10743595				
	Filing Date		2003-12-22				
	First Named Inventor	Haral	ld van Kampen				
	Art Unit		2661				
	Examiner Name	CHIN	, WELLINGTON				
	Attorney Docket Number		Kampen 1-13				

				Attorr	ney Doc	ket Number		Kampen 1-13				
					U.S.I	PATENTS				Remove		-
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	ate Name of Patentee or Applicant Re		Releva	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	6067297		2000-0	5-23	Bearth, Rober	rt					
	2	6463307		2002-1	0-08	Larsson et al.						
If you wish	to a	dd additional U.S. Pate	nt citatio	n inform	nation pl	ease click the	A	dd button.	_	Add		_
			U.S.P	ATENT	APPLIC	CATION PUB	LIC	CATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Patentee or Applican of cited Document			Releva		ines where es or Relev	
	1	20020132603		2002-0	9-19	Lindskog et a	d.					
If you wish	n to ac	l dd additional U.S. Publ	shed Ap	plication	n citation	n information	ple	ase click the Ad	d button	Add		_
				FORE	GN PAT	ENT DOCUM	AE)	NTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4		A	Name of Patente Applicant of cited Document	e or	where Rele	or Relevant	١
	1											
If you wish	n to a	dd additional Foreign P							button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CL	UMENTS		Remove		

	Application Number		10743595		
INFORMATION DIGGS COURT	Filing Date		2003-12-22		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Haral	ild van Kampen		
(Not for submission under 37 CFR 1.99)	Art Unit		2661		
(Not for submission under 57 GFR 1.33)	Examiner Name CHIN		, WELLINGTON		
	Attorney Docket Numb	er	Kampen 1-13		

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not clastion is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Patent Documents at Iwen USPTO_GDV or MPEP 901.04. 2 Enter office that issued the document, by the In-clearing code (WIPO Standard ST3.). 3 Fee Implanees patent documents, the advantage on the parent of the Emperor unsprinced the seast include of the patent of the patent of the patent of the patent or the Colument by the appropriate symbols as advantaged on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark then if Employin languages the residence is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10743595		
Filing Date		2003-12-22		
First Named Inventor	Haral	d van Kampen		
Art Unit		2661		
Examiner Name CHIN		, WELLINGTON		
Attorney Docket Number		Kampen 1-13		

CERTIFICATION STATEMENT

Please see	37	CER	1 97	and	1 08	to	maka	the	annro	nriata	coloction	v/e)·	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Yuri Gruzdkov/	Date (YYYY-MM-DD)	2006-07-07	
Name/Print	Yun Gruzdkov	Registration Number	50.762	

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.